StockNews.com began coverage on shares of Brooklyn ImmunoTherapeutics (NYSE:BTX – Free Report) in a research report sent to investors on Sunday morning. The firm issued a hold rating on the stock.
Brooklyn ImmunoTherapeutics Stock Performance
BTX stock opened at $1.80 on Friday. Brooklyn ImmunoTherapeutics has a fifty-two week low of $0.17 and a fifty-two week high of $10.10. The business’s 50 day moving average price is $1.79 and its two-hundred day moving average price is $1.98. The company has a market capitalization of $105.89 million, a price-to-earnings ratio of -0.77 and a beta of 4.61.
Brooklyn ImmunoTherapeutics Company Profile
Featured Stories
- Five stocks we like better than Brooklyn ImmunoTherapeutics
- What is the NASDAQ Stock Exchange?
- Target Hits the Mark: Q2 Earnings Exceed Expectations
- Insider Buying Explained: What Investors Need to Know
- Is Tesla’s Rebound Just Starting? Why You Should Consider Buying
- Election Stocks: How Elections Affect the Stock Market
- Stanley Druckenmiller’s Latest Bet: MELI—Should You Follow Suit?
Receive News & Ratings for Brooklyn ImmunoTherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brooklyn ImmunoTherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.